Overview
Vitalay F. is co-founder and CEO of Numenos AI[1][3], a company developing foundation model architectures designed to discover fundamental biological principles from individual patient data[2]. Fomin's approach integrates biologically siloed data across disease areas including oncology, rare diseases, cardiovascular, and immunology to identify invariant biological mechanisms applicable across contexts[2]. Prior to founding Numenos in April 2023[3], Fomin worked as a data scientist at Roche from April 2019 to January 2023[5] and as associate director at Otsuka Pharmaceutical Companies from February 2022 to June 2023[4]. Fomin also served as CEO and co-founder of pMedica from January 2015 to March 2018[7]. Fomin holds a PhD in biochemistry from Columbia University, completed in December 2011[6], and a BS in biology from Columbia University[9].
Profile introduction
Vitalay Fomin is the CEO and co-founder of Numenos, a company pioneering foundation model architectures that discover fundamental biological principles from individual patient data. Unlike traditional machine learning approaches that treat diseases as isolated categories, Numenos has built a unified infrastructure that integrates biologically siloed data across disease areas (oncology, rare diseases, cardiovascular, immunology) enabling the discovery of invariant biological mechanisms that apply across contexts. Previously, at Roche Research & Early Development Informatics in New York, Vitala…
Career history
- Co-Founder & CEOApr 2023 to presentNumenos AI
- Associate DirectorFeb 2022 to Jun 2023Otsuka Pharmaceutical Companies (U.S.)
- Data ScientistApr 2019 to Jan 2023Roche
- Doctor of Philosophy (PhD), BiochemistryDec 2011 to Apr 2019Columbia University in the City of New York
- CEO and CO-FOUNDERJan 2015 to Mar 2018pMedica
Education
Doctor of Philosophy - PhDColumbia University
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.